MMP-14 and MMP-9 are two well established cancer targets for which no specific clinically relevant inhibitor is available. Using a powerful combination of computational design and yeast surface display technology, we engineered such an inhibitor starting from a non-specific MMP inhibitor, N-TIMP2. The engineered purified N-TIMP2 variants showed enhanced specificity towards MMP-14 and MMP-9 relative to a panel of off-target MMPs. MMP-specific N-TIMP2 sequence signatures were obtained that could be understood from the structural perspective of MMP/N-TIMP2 interactions. Our MMP-9 inhibitor exhibited 1000-fold preference for MMP-9 vs. MMP-14, which is likely to translate into significant differences under physiological conditions. Our results provide new insights regarding evolution of promiscuous proteins and optimization strategies for design of inhibitors with single-target specificities.
Introduction
Matrix metalloproteinases (MMPs) belong to a family of over twenty MMPs and twelve homologous ADAMs proteases, enzymes that are respectively responsible for degradation of the extracellular matrix and membrane proteins [1] . MMPs differ in domain composition and size, yet all of them share a similar catalytic domain with a Zn 2+ ion in the active site. MMPs are first produced in an inactive form and are activated by the cleavage of a pro-domain by certain MMPs or other proteases.
MMP function is important in biological processes involving tissue remodeling, such as development and immune response [2] .
Upregulation of MMPs or lack of MMP inhibition leads to various diseases including arthritis, chronic obstructive pulmonary disease, inflammatory bowel diseases, sepsis and various types of cancer [2] . In cancer, some MMPs play a crucial role in angiogenesis, metastasis and other aspects of tumor growth through cleavage and activation of a variety of different proteins [3] [4] [5] . The unhindered digestion of the extracellular matrix by specific MMPs such as MMP-2 and MMP-9 allows for tumor progression and cancer cells to invade and traverse from one tissue to another, resulting in the appearance of new tumors, and the activity of other MMPs, such as membrane bound MMP-14 (also called MT1-MMP) that promote cancer by activating other MMP family members [6] . Inhibition of particular MMPs could hence reverse cancer progression and reduce the spread of cancer cells.
Due to their importance to disease, MMPs have been the target for drug design efforts over the past thirty years, and several small molecules were developed early on for MMP inhibition [3] . Yet, all of them have failed in clinical trials [7] . The major reason for the failure of these drugs was their low specificity: small-molecule MMP inhibitors were designed to bind to the active-site Zn 2+ and hence reacted with Zn 2+ and other heavy metals in various proteins in the body and thus were highly toxic. In addition, drugs directed at multiple MMP family members elicited unexpected effects due to diverse MMP activities. In fact, some MMPs have been documented to play essential roles and even antitumorigenic roles [8] [9] [10] , pointing to the importance of developing selective inhibitors that target only one or a narrow range of MMPs.
Such high specificity, while difficult to obtain with small molecules, could be achieved in protein-based inhibitors [11] [12] [13] [14] . Proteins possess a greater potential for high specificity due to their large interaction surface that involves not only the highly conserved catalytic site but also more variable surrounding residues. In this respect, antibodies have been developed that specifically target MMP-9 [15] and MMP-14 [16, 17] , proving the possibility of engineering a type-specific MMP inhibitor. Besides antibodies, other attractive scaffolds for MMP inhibitor design are the natural broad inhibitors of the MMP family, tissue inhibitors of metalloproteinases (TIMPs). The mammalian TIMPs include four homologous proteins (TIMP1-4) that exhibit slightly different preferences for various MMPs [18] . The advantage of using TIMPs for MMP inhibitor design is their already high affinity towards various MMPs (10 -10 -10 -9 M), no toxicity, no immunogenicity and their smaller size that facilitates their easy production by microbial expression and supplies them with better tissue perfusion rates in comparison to antibodies.
To this end, TIMPs have been already a subject of several protein engineering studies [19] [20] [21] [22] .
For this study, as a scaffold for MMP inhibitor design, we chose the N-terminal domain of TIMP-2 (N-TIMP2), consisting of 126 amino acids. The isolated N-TIMP2 remains a strong inhibitor of various MMPs [23, 24] and is more easily expressed in bacterial cultures compared to the full-length TIMP2.
Most importantly, N-TIMP2 has a smaller protein interaction network compared to the full length protein; it cannot participate in interactions with the MMP hemopexin-like domain, thus losing its ability to activate certain MMPs [25] . The crystal structures of TIMP2-MMP complexes [19, [26] [27] [28] [29] show that binding of N-TIMP2 to MMPs is mediated by four discontinuous regions ( Figure 1A ). These regions include the N-TIMP2 N-terminal region that comes in close proximity to the highly-conserved enzyme active site and three loops (35-42, 66-72, and 97-99). While previous TIMP protein engineering studies mostly focused on mutating the N-terminal residues, we decided to focus on the loops that interact with less conserved residues further away from the enzyme active site. Such a strategy is likely to yield inhibitors that can discriminate between different MMPs.
The goal of this work was to evolve the multispecific inhibitor N-TIMP2 into a high-affinity and high-specificity inhibitor of one out of two different MMP family members: a membrane-bound MMP, MMP-14, or the secreted gelatinase, MMP-9. The catalytic domains of MMP-14 and MMP-9 (termed MMP-14 CAT and MMP-9 CAT , respectively) are structurally very similar (RMSD of 0.6 Å) showing an overall sequence identity of 45% and 66% identity among the residues that contact N-TIMP2 ( Figure 1A and B). N-TIMP2 is a prototypical multispecific protein [30], whose sequence is a compromise for interactions with all MMP family members and thus is not optimal for interactions with each specific MMP [31, 32] . Recent studies on other multispecific proteins demonstrated that such proteins could be converted into highly specific binders of a particular target either through computational methods [33] [34] [35] or directed evolution approaches [36, 37] .
In our previous work [38] , we used the computational saturation mutagenesis protocol [35, 39] to explore the effect of all single mutations in the N-TIMP2 binding interface on N-TIMP2's binding affinity and specificity to MMP-14 CAT. Our computational results pointed to a high frequency of mutations that enhance N-TIMP2's affinity and specificity toward MMP-14. Experimental results confirmed our predictions, identifying ten affinity-enhancing mutations and eleven specificity-enhancing mutations for MMP-14 relative to MMP-9. However, the enhancement in binding specificity remained relatively low for single mutations, not exceeding a factor of ten. Clearly, introduction of multiple mutations into N-TIMP2 would be required to achieve further improvements. In the present study, we thus constructed a small combinatorial library of N-TIMP2 mutants that is rich in affinity-and specificity-enhancing mutations and used yeast surface display (YSD) technology [40] to select N-TIMP2 variants that bind selectively to MMP-14 CAT and separately to MMP-9 CAT . Our results show that selective N-TIMP2 inhibitors could be found and the acquired mutations contained specific signatures that define specificity for each of the MMPs.
Materials and Methods

Preparation of N-TIMP2 Libraries for YSD
The pCHA yeast surface display plasmid [41] was used for displaying N-TIMP2 WT and mutants on the yeast surface with a free N-terminus. The library of N-TIMP2 mutants was constructed using an assembly PCR method (see Supporting Information) randomizing positions 4, 6, 35, 38, 68, 71, 97, 99 to particular amino acids specified in Table 1 . The transformation of the library to yeast was performed by simultaneously transforming the amplified mutant N-TIMP2 fragments with a pCHA[VK1] vector linearized by BamHI-HF and Nhe-HF restriction enzymes (New England Biolabs) into a competent EBY100 Saccharomyces cerevisiae yeast strain by electroporation.
FACS Analysis and Sorting
Growth of yeast (EBY100) cells, FACS analyses and sorting of libraries was performed as in Arkadash et al. [42] . For the detection of binding to MMP-14 CAT , the cells were incubated with MMP-14 CAT labelled with DyLight-488 for 1 hour on ice. An identical process was performed for detection of MMP-9 CAT binding, where MMP-9 CAT is labelled with DyLight-650. Three rounds of selection were performed with lowering the concentration of the target MMP and raising the concentration of the off-target MMP (see Figure S2 ).
Yeast Library Sequencing
After each round of sorting, cells collected from the flow cytometry sorter were grown in SDCAA medium (0.54% Na 2 HPO 4 , 0.86% Na 2 HPO 4 •H 2 O, 1.5% agar, 2% dextrose, 0.67% yeast nitrogen base, 0.5% Bacto casamino acids) supplemented with chloramphenicol (25 µg/ml) for ~36 hrs. 10 µl of resulting culture was diluted in SDCAA to a volume final of 2 ml, 20 µl of this diluted solution was plated on SDCAA agar plates supplemented with chloramphenicol (25 µg/ml). Single colonies were picked and served as input for colony PCR and subsequent sequencing (see Supporting Information for details).
N-TIMP2 Expression and Purification
The N-TIMP2 mutant genes were transferred from the pCHA plasmid obtained from yeast lysates (lysed by boiling in 0.02 M NaOH) to the pPICZαA P. pastoris expression vector by transfer PCR [43] .
PCR products were subsequently linearized with SacI (New England Biolabs) transformed into chemical competent DH5α E. coli. The transformed bacteria were plated on LB agar plates containing 25 μ g/ml Zeocin (InvivoGen, CA, USA). After an overnight incubation at 37°C, three colonies were chosen for growth in liquid LB medium at 37°C for ~16 hours, the plasmid was purified, and the correct sequence was verified by sequencing. Bacterial cultures possessing plasmids encoding for the correct sequence were grown for ~16 hours at 37°C for large scale plasmid purification by maxiprep (Geneaid, Taiwan).
The purified plasmid was then transformed to X33 P. pastoris yeast and recombinant protein production was induced as described in our previous work [42] .
The proteins were purified as described in our previous work [42] . Protein concentrations were determined by UV-Vis absorbance at 280 nm, with an extinction coefficient (ε 280 ) of 13,325 M -1 cm -1 for WT N-TIMP2 and all its mutants.
MMP Enzyme Expression and Purification
The human MMP-9 catalytic domain (MMP-9 CAT ), residues 107-215, 391-443, was expressed and purified as previously described [15] , with the following modifications; the gene was expressed in 
Enzymatic Activity Assay of N-TIMP2:MMP binding
Varying concentrations of N-TIMP2 were incubated with 0.5 nM MMP-1 CAT , 6 nM MMP-2 CAT , 0.1 nM MMP-9 CAT , 0.5 nM MMP-10 CAT , 0.2 nM MMP-14 CAT under conditions similar to that described in [42] .
Fluorescence resulting from cleavage of fluorogenic substrate was measured at 395 nm, at least every ten seconds for at least 6 minutes, immediately after addition of fluorogenic substrate with irradiation at 325 nm on a Biotek Synergy H1 plate reader (BioTek, VT, USA). At least three assays were performed for each N-TIMP2 protein.
K i app Determination
Initial velocities of the enzymatic (MMP) cleavage of the fluorogenic substrate were derived from the fluorescence generated by this cleavage. Fraction of MMP activity was determined from the enzymatic assay, expressed as the inhibited velocity (V i ) divided by the uninhibited velocity (V 0 ), and was plotted against the corresponding concentration of N-TIMP2. From this plot the apparent K i (K i app ) value was solved for based on the following equation [45] :
f= fraction of activity, V i /V 0 Specificity for MMP-X relative to MMP-Y was calculated according to the following formula:
Structural Modeling
Modeling of N-TIMP2 in complex with MMP-14 CAT and MMP-9 CAT was performed as in our previous study [38] . For modeling the mutations in the N-TIMP2 binding interface, the energy function optimized by Sharabi et al. [38, 46] was used. All mutations present in each N-TIMP2 mutant were simultaneously introduced into N-TIMP2 first with no backbone flexibility and then using backbone flexibility using the RosettaBackrub server [47] . The output of this protocol was a multiple-mutant structure along with its Δ Δ G bind value. The difference in molecular interactions due to introduction of each mutation was analyzed in the context of both structures, the N-TIMP2/MMP-14 CAT and the N-TIMP2/MMP-9 CAT structures to determine which type of interactions cause a specificity switch.
Results
N-TIMP2 library construction
To obtain inhibitors that bind to either MMP-14 CAT or MMP-9 CAT with high affinity and high specificity, we constructed a small computationally designed combinatorial library that mutated only a few positions on the N-TIMP2 binding interface. We randomized eight positions in the direct N-TIMP2 binding interface ( Figure 1A ) to a limited set of amino acids, including either WT choice or mutation(s) observed to enhance binding affinity and/or specificity towards MMP-14 CAT in our previous study [38] (Table 1) . Additional amino acid choices were included in the library when no degenerate codon could be found to simultaneously encode for only the desired choices. The designed library included 68480 different full-length N-TIMP2 sequences, and was enriched in sequences with enhanced specificity towards MMP-14 CAT . Sequencing of the library before selective sorting revealed that the clones in the library contained on average of 6±2 mutations per gene.
Selection of high specificity MMP-9 and MMP-14 binders. YSD technology was used to select specific binders for MMP-9 CAT and MMP-14 CAT in two parallel experiments. The N-TIMP2 library was expressed on the surface of yeast cells using the pCHA expression vector, where the yeast protein Aga2p is fused to the C-terminus of N-TIMP2, leaving the N-terminus of the N-TIMP2 free for interaction with the target MMPs (Figure 2A ). This arrangement is crucial since the N-terminus of N-TIMP2 mediates binding to the MMP active site and thereby facilitates proper inhibition of MMPs, as could be inferred from the crystal structure of N-TIMP2/MMP complexes and was confirmed in previous experiments [42, [48] [49] [50] . (Figure 3A, B) . The most outstanding result for the MMP-14 CAT selection is a unanimous consensus to asparagine at position 71 that replaces a WT valine ( Figure 3A ).
The sequences of N-TIMP2 mutants in the MMP-9 CAT selection show a substantial consensus at position 4 for proline as opposed to the WT serine as well as a mutation from valine to isoleucine at position 71.
At position 38, glutamine predominates the MMP-14 CAT selection, but a wild-type asparagine appears most frequently in the MMP-9 CAT selection. Positions 4, 38, and 71 hence, stand out as the most important specificity determining positions for MMP-14 and MMP-9 binding.
Understanding specificity signatures through modeling
To understand the nature of enhanced specificity, we performed structural modeling of the engineered N-TIMP2 mutants when interacting with MMP-14 and MMP-9. At position 4, we see a strong preference for glutamate in the MMP-14 CAT selection while proline clearly predominates the MMP-9 CAT selection. Our modeling shows that a glutamate at position 4 can form an intermolecular hydrogen bond with N231 on MMP-14 CAT but not with MMP-9 CAT ( Figure 4A) . A proline at position 4 fits better in the more hydrophobic environment of MMP-9 CAT but causes a steric clash with MMP-14 CAT , which could be removed only through substantial backbone conformational changes ( Figure 4A ). At position 38, glutamine predominates in the MMP-14 CAT selection, but a wild-type asparagine appears most frequently in the MMP-9 CAT selection.
According to our modeling, Q38 makes a favorable hydrogen bond with N208 on MMP-14 CAT , but cannot make such a bond with the corresponding G197 on MMP-9 CAT ( Figure 4B ). It should be noted that glycine is conserved at this position in all the MMPs tested in this work except for MMP-14 CAT where this position is occupied by asparagine ( Figure 1B) . In the MMP-9 CAT selection, mutation to isoleucine predominates at position 71. This isoleucine packs against hydrophobic residues on MMP-9 CAT , namely F192 and Y179. Position 71 is highly enriched for a mutation to asparagine in the MMP-14 CAT selection;
the asparagine could make a favorable hydrogen bond with Y203 on MMP-14 CAT (Figure 4C ).
Purification and characterization of MMP-9 CAT and MMP-14 CAT inhibitors.
To verify the success in binding specificity enhancement, six random N-TIMP2 mutants from each of the selection experiments were individually assessed for binding to MMP-14 CAT and MMP-9 CAT while displayed on the yeast surface ( Figure 5A and C) . The specificity of each mutant was evaluated by determining the ratio of the binding signal for the target MMP to that of the off-target MMP and then dividing by the same ratio for WT N-TIMP2. All tested mutants showed higher specificity towards the target MMP compared to that of WT N-TIMP2. In the MMP-14 selection experiment, we selected mutants 14D-4 and 14D-6 for further purification and characterization since they exhibited the highest specificity signal ( Figure 5A ). In the MMP-9 selection experiment, we chose mutants 9D-2 and 9D-6 since mutant 9D-2 exhibited the highest specificity signal ( Figure 5C ), whereas mutant 9D-6 recurred 3 out of 15 times among the sequenced clones. Table 2 lists the mutations present in the N-TIMP2 mutants chosen for purification and characterization from the designed library.
The four selected N-TIMP2 mutants and the WT N-TIMP2 were expressed and purified from Pichia pastoris yeast cells, which secrete the properly folded N-TIMP2 protein (Supplementary Figure   S2 ) [50, 51] . The K i app of the inhibition of MMP-14 CAT and MMP-9 CAT by N-TIMP2 mutants was determined using an MMP enzyme activity assay in the absence and the presence of the N-TIMP2
inhibitor as previously described ( Figure 5B and D) [38] . Table 3 summarizes the K i app values obtained for each N-TIMP2 mutant, for inhibition of MMP-14 CAT and MMP-9 CAT . All tested mutants showed a substantial increase in binding specificity towards the target MMP (Table 3 and 4). The best mutant from the MMP-14 CAT selection, 14D-6, with 8 mutations exhibited a specificity shift of ~60-fold. This specificity increase is due to ~3-fold improvement in affinity to the target MMP-14 and ~20-fold decrease in affinity to MMP-9 relative to WT N-TIMP2. The two expressed N-TIMP2 mutants from the MMP-9 CAT selection show similar double digit specificity enhancements values. The best mutant, 9D-6, exhibits a 44-fold increase in binding specificity to MMP-9 CAT over MMP-14 CAT, but a slightly worse affinity to MMP-9 compared to WT N-TIMP2. Thus, the specificity increase in this mutant comes through a great reduction in affinity to MMP-14 CAT relative to WT N-TIMP2. Note that the 9D-6 mutant exhibits nearly 1000-fold better binding affinity towards MMP-9 CAT vs. MMP-14 CAT (Table 3) . Such high affinity differences, should be significant for preferential inhibition of MMP-9 but not MMP-14 in cellular environments.
To determine general binding specificity of our engineered MMP-14 CAT and MMP-9 CAT inhibitors, we measured their ability to inhibit a panel of additional MMP types, MMP-1 CAT (collagenase), MMP-2 CAT (gelatinase) and MMP-10 CAT (stromelysin). Table 4 shows that engineered N-TIMP2 mutants generally show reduced affinity to off-target MMPs that have not been used in our selection experiments.
Higher specificity shifts are observed in the MMP-14 CAT selection, where mutant 14D-6 exhibits a 294fold preference for MMP-14 CAT over MMP-10 CAT . The N-TIMP2 mutants from the MMP-9 CAT selection, especially 9D-6, are superior in absolute values of K i app , able to inhibit MMP-9 CAT at least 100 times better relative to all measured off-target MMPs ( Table 3 ).
Discussion
Designing inhibitors that act against a single or narrow range of MMPs is clearly important for targeting MMPs in diseases and much effort in this direction has been recently reported [52] . In this work, we attempted to engineer such an inhibitor starting from the natural broad MMP inhibitor, N-TIMP2.
Previously, we showed that the N-TIMP2/MMP binding interface is not optimized and contains many affinity-and specificity-enhancing mutations [38] . Specifically, positions 4, 35, 38 and 68 on TIMP were determined to be cold spots of binding [53] , i.e. positions where several different mutations lead to increase in binding affinity towards MMP-14. We also determined that single mutations on N-TIMP2 in general, do not increase binding specificity by more than one order of magnitude. Here, we demonstrate that incorporation of 5-8 mutations into the N-TIMP2 sequence results in two orders of magnitude enhancement in binding specificity towards the target MMP. Among the combination of mutations found in this study, we frequently observe single mutations, previously identified as specificity-enhancing (e. g.
at positions 4, 38, and 71). However, beneficial single mutations, when incorporated together, result in negative cooperativity, producing smaller specificity shifts for multiple mutants compared to the sum of shifts for single mutations.
As in many other engineering studies, the N-TIMP2 mutants reported here showed reduction of binding not only to the MMP used as a competitor but also to off-target MMPs not used in the selection procedure: MMP-1 CAT , MMP-2 CAT , and MMP-10 CAT . The amount of affinity reduction to off-target MMPs correlates well with the interface sequence identity between the target and the off-target MMP ( Figure 1B) , exhibiting the lowest specificity shift against MMP-1 CAT in the MMP-14 CAT selection experiment and MMP-1 CAT and MMP-2 CAT in the MMP-9 CAT selection experiment. These results demonstrate that when similarity of off-targets is highest, the specificity for the target MMP is more difficult to achieve. Furthermore, the relatively small library of N-TIMP2 mutants, containing only ~70,000 mutants, could be used to evolve this protein to interact specifically with both MMP-14 and MMP-9. The same library is likely to produce specific binders for other MMPs, opening the way to future engineering studies.
The reported N-TIMP2 mutants exhibit specificity shifts similar to what has been observed in previous N-TIMP2 engineering studies. In our recent study, N-TIMP2 was engineered using a much larger library of 10 8 N-TIMP2 mutants and a more stringent selection procedure that included only the desired target, MMP-14 CAT [42] . In that work, 880-fold improvement in binding affinity for MMP-14 CAT was obtained, but small improvements in affinity were also reported for all but one of the off-target We report for the first time, N-TIMP2 mutants engineered for MMP-9 CAT binding that exhibits 1000-fold better K i app for MMP-9 CAT vs. MMP-14 CAT and large discriminations against other tested MMPs. Such a mutant is likely to selectively inhibit MMP-9 under physiological conditions and thus could serve to probe the role of MMP-9 in various diseases. As several of our previously reported MMP-14-specific N-TIMP2 variants have already showed high potency in inhibiting cancer-related MMP activity in various cellular assays [42] , the MMP-14-and MMP-9-specific mutants reported in this study present interesting candidates for further testing in cellular and in vivo studies. Overall Table 3 : Inhibitory activities of the purified proteins. Purified N-TIMP2 mutants were assayed for their ability to inhibit MMP-14 CAT and MMP-9 CAT . K i app values were obtained from at least three such
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